OncoSec Medical Inc (ONCSQ)

[hschlauch]

I would have to listen to the call again to try to understand the details of the amended protocol proposal mentioned by Dr. Gargosky.

I would be very pleased to see responses in the 30% range for the phase II combo trial, simply because there are other combination trials with pembrolizumab and other checkpoint inhibitors that reach 58% ORR in metastatic melanoma. While no two trials can be compared against one another, there appears to be consistency in ORR with these combo trials hovering around that 58% mark. In my estimates, this would be nearly-equivalent to a 28%-38% ORR in Oncosec's phase II combo trial with pembro. Dr. Gargosky does indeed appear to be happy with what they are observing, and I'm sure KOLs will be looking at individual case studies to determine the data significance. For example, what are the TIL phenotype profiles prior to treatment? No one understands the significance of the data like the oncologists.